Get the Stockscreener App
3.23
2.87%
0.09
Pre-market:
3.23
Achieve Life Sciences Inc stock is traded at $3.23, with a volume of 504.19K.
It is up +2.87% in the last 24 hours and down -30.09% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$3.14
Open:
$3.1
24h Volume:
504.19K
Relative Volume:
0.73
Market Cap:
$171.97M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-2.4946
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
+11.76%
1M Performance:
-30.09%
6M Performance:
+1.25%
1Y Performance:
+26.67%
1-Day Range:
$3.05
$3.32
1-Week Range:
$2.62
$3.32
52-Week Range:
$1.84
$6.025
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
3.23 | 171.97M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2025 earnings call transcript - MSN
Achieve Life Sciences flags FDA observations while pushing launch to 2027 for smoking cessation med - msn.com
ACHV Technical Analysis & Stock Price Forecast - Intellectia AI
Achieve Life Sciences Inc (SP4P.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Achieve Life Sciences: The Recent Sell-Off Skews The Outcomes (NASDAQ:ACHV) - Seeking Alpha
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect - Finviz
In 3,014 subjects, Caris blood test reached 99.2% specificity - stocktitan.net
Aug Analyst Calls: Will Achieve Life Sciences Inc benefit from government policyMarket Rally & Weekly Momentum Stock Picks - baoquankhu1.vn
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Achieve Life Sciences reports fourth-quarter results in line with expectations - MSN
Research Analysts Offer Predictions for ACHV FY2026 Earnings - Defense World
What is Zacks Research's Estimate for ACHV FY2026 Earnings? - MarketBeat
HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings - MarketBeat
What is HC Wainwright’s Estimate for ACHV Q1 Earnings? - Defense World
Aug Macro: Whats the fair value of Achieve Life Sciences Inc stockStock Surge & Smart Allocation Stock Reports - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - The Globe and Mail
Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation - Seeking Alpha
Achieve Life Sciences publishes cytisinicline receptor study By Investing.com - Investing.com Canada
Achieve Life Sciences publishes cytisinicline receptor study - Investing.com
Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med - Benzinga
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2025 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability - The Spec
Q1 Earnings Estimate for ACHV Issued By HC Wainwright - MarketBeat
Execution Risks Cloud Achieve Life Sciences’ Commercial Plans for Cytisinicline - The Globe and Mail
Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright Reiterates "Buy" Rating for Achieve Life Sciences (NASDAQ:ACHV) - MarketBeat
H.C. Wainwright reiterates Buy on Achieve Life Sciences stock By Investing.com - Investing.com Canada
Achieve Life Sciences (ACHV): HC Wainwright & Co. Reiterates Buy Rating | ACHV Stock News - GuruFocus
Earnings Call Summary | Achieve Life(ACHV.US) Q4 2025 Earnings Conference - 富途牛牛
Achieve Life Sciences outlines first half 2027 cytisinicline launch supported by US manufacturing shift and AI-driven commercialization - MSN
Achieve Life Sciences stock falls as commercial launch pushed to 2027 - ca.investing.com
Achieve Life Sciences Inc (ACHV) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Achieve Life Sciences Inc (ACHV) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - MarketScreener
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Achieve Life Sciences Reports 2025 Financial Results, Advances Cytisinicline NDA for Smoking and Vaping Cessation, Announces U.S. Manufacturing Partnership with Adare Pharma Solutions 12 - Minichart
Achieve Life Sciences Sees Unusually Large Options Volume (NASDAQ:ACHV) - marketbeat.com
Achieve Life Sciences Q4 Earnings Call Highlights - MarketBeat
Achieve Life Sciences, Inc. 2025 10-K Annual Report: Business Overview, Risk Factors, and Financial Highlights - Minichart
ACHV: Cytisinicline NDA accepted; U.S. launch planned for 1H 2027 with robust supply and payer strategy - TradingView
Earnings call transcript: Achieve Life Sciences Q4 2025 reports stable EPS, stock dips - Investing.com India
ACHV: NDA review progresses for cytisinicline, with U.S. launch targeted for 1H 2027 amid strong clinical data - TradingView
Achieve (ACHV) Advances Cytisinicline for Smoking Cessation Solu - GuruFocus
Achieve Life Sciences, Inc. (ACHV) Reports Wider Q4 Loss Than Expected - AlphaStreet
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Achieve Life Sciences meets fourth quarter estimates By Investing.com - Investing.com Australia
Achieve Life Sciences (NASDAQ:ACHV) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Achieve Life Sciences meets fourth quarter estimates - Investing.com
ACHIEVE LIFE SCIENCES ($ACHV) Releases Q4 2025 Earnings - Quiver Quantitative
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):